Cmet rna car t cells

Cmet rna car t cells - a preparation of autologous t-lymphocytes that have been electroporated with an mrna encoding a chimeric antigen receptor (car) consisting of an anti-human hepatocyte growth factor receptor (hgfr or cmet) scfv (single chain variable fragment) and the zeta chain of the tcr/cd3 complex (cd3-zeta) coupled to the co-stimulatory molecule 4-1bb (cd137), with potential antineoplastic activities. Upon intratumoral administration, cmet car-mrna electroporated autologous t lymphocytes direct t-cells to cmet-expressing tumor cells, which induces a selective toxicity in cmet-expressing tumor cells and causes tumor cell lysis. The 4-1bb co-stimulatory molecule signaling domain enhances activation and signaling after recognition of cmet. The inclusion of the 4-1bb signaling domain may increase the antitumor activity as compared to the inclusion of the cd3-zeta chain alone. The mrna car is expressed for a limited amount of time, which can prevent serious, unforeseen side effects. Cmet, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis. See cmet car-mrna electroporated autologous t lymphocytes

Latest articles Cmet rna car t cells

• UpToDate on Cmet rna car t cells

• Most recent articles
• Most cited
• Ongoing trials

edit 

WikiMD needs you!

This WikiMD article Cmet rna car t cells is a stub.
If you are a healthcare professional familiar with the topic Cmet rna car t cells, or
A subject matter expert or authority on Cmet rna car t cells, you can help us.
About | Mission | Paid editors welcome!

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Cmet rna car t cells for any updates.